Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

Inclusion Criteria

• •Patients (age between 18-85 years) with acute decompensated heart failure (HF).
• •Brain Natriuretic Peptide (BNP) \>100 pg/ml, or N-terminal pro-BNP (NT-proBNP)\>300 pg/ml as defined by current clinical guidelines for the diagnosis of acute decompensated HF (European Society of Cardiology 2016 HF guideline)
• •Patients with diabetes mellitus type 2 or impaired glucose tolerance as defined by current clinical guidelines (German and International Diabetes Society 2016: HbA1c\>6.5 % (upper limit for this clinical trial 12 %) or fasting glucose \>7.0 mmol/l or any incidental glucose level \>11.1 mmol/l or abnormal oral glucose tolerance test with 2h plasma glucose \>7.8 mmol/l) or on antidiabetic medication or antidiabetic diet or patients with normal Glucose tolerance
• •Patients without cognitive impairment, i.e. they must be capable of understanding the nature, significance and implications of the clinical trial and to form a rational intention in the light of the facts
• •Written informed consent obtained
• •For women with childbearing potential (until 2 years after menopause):
• •* Negative pregnancy test
• •* regular and correct use of a highly effective contraceptive method with an error rate of \<1% per year (e.g. combined (estrogen and progesteron) hormonal contraception (oral, intravaginal, transdermal), progesteron-only hormonal contraception (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS) tubal ligation (female sterilization), hormon donating intrauterine device ("hormonal spiral"), double barrier methods, sexual abstinence, vasectomy of the partner)